ArticleJACC. Advances2026
Safety and Outcomes of Concomitant Left Atrial Appendage Occlusion and Atrial Fibrillation Ablation.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPerforming atrial fibrillation (AF) catheter ablation and percutaneous left atrial appendage occlusion (LAAO) during a single procedure may improve efficiency and reduce cumulative procedural risk. However, concerns remain regarding potential increases in periprocedural and longer-term complications, including stroke, pericardial effusion, device leak, and device-related thrombus. Evidence evaluating the safety of this concomitant strategy remains limited.
objectivesThe objectives of the study was to compare the safety and short- and long-term outcomes of concomitant AF ablation plus LAAO vs LAAO alone.
methodsWe conducted a retrospective cohort study using the TriNetX U.S. Collaborative Network, identifying adults (≥18 years) with AF who underwent percutaneous LAAO between January 2015 and February 2026. Patients undergoing AF ablation on the same day as LAAO were compared with those undergoing LAAO alone. After 1:1 propensity score matching for demographics, comorbidities, cardiovascular medications, and laboratory values, 1,899 patients were included in each group. Outcomes including all-cause mortality, stroke, device leak, device-related thrombus, pericardial effusion, and pericardiocentesis were assessed at 7 days, 90 days, and 1 year using cumulative incidence and Cox proportional hazards models.
resultsBaseline characteristics were well balanced after matching. Concomitant AF ablation was not associated with increased adverse events. Mortality was similar at 90 days (0.6% vs 0.6%; HR: 1.00; 95% CI: 0.43-2.32) and 1 year (1.4% vs 1.5%; HR: 0.97; 95% CI: 0.58-1.63). At 90 days, rates of stroke, device leak, and device-related thrombus were comparable between groups, with no differences observed at 1 year.
conclusionsIn this large, propensity-matched analysis, concomitant AF ablation at the time of LAAO was not associated with increased early or 1-year complications, supporting the safety of a combined approach in appropriately selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.